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Background: Penetrating keratoplasty can commonly restore vision in corneal blindness. However, immunological
graft reactions may induce irreversible graft failure in a substantial percentage. Repeat keratoplasties in turn are
associated with increased risk of graft failure and possibly irreversible blindness. Topical as well as systemic
immunosuppressants are administered for prophylaxis. However, severe adverse effects limit long-term usage.
By contrast, matching for transplantation antigens might be effective for a long time.
Methods: FANCY is a prospective, controlled, randomised, double-blind, multi-centre clinical trial with two parallel
arms. The primary objective is to evaluate superiority of the proposed HLA matching strategy in comparison to
random graft assignment with respect to the primary endpoint ‘time to first endothelial graft rejection’. Relevant
inclusion criteria are age over 18 years and waiting for penetrating or endothelial lamellar keratoplasty. The most
important exclusion criteria are abuse of medication and/or drugs and an anticipated waiting time for an HLA
match longer than 6 months. After randomisation, patients either receive a HLA-matched graft (experimental
intervention) or a random graft (control intervention). The calculated sample size is 620 patients. The trial started in
2009 with a recruitment period of 24 months. A total of 654 patients were included during this time.
Discussion: The primary goal of FANCY is to assess whether histocompatibility matching is feasible and effective in
the broad clinical routine. However, during the course of the trial, the landscape of keratoplasty changed due to
the rise of Descemet Membrane Endothelial Keratoplasty (DMEK). Nowadays, immune reactions are confined mostly
to the ‘high-risk’ subgroups. If we would design FANCY in 2014, we would narrow down the inclusion criteria to
include only the high risk patients and accept longer waiting times for a matching donor here.
Trial registration: The unique identifying number of the FANCY trial is NCT00810472.
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operational toleranceBackground
Graft rejection after keratoplasty
Corneal diseases are among the five most common
causes of blindness. FANCY was designed back in 2007.
At that time, penetrating keratoplasty was the undis-
puted gold standard for corneal transplantation. This
procedure can restore vision in the majority of affected pa-
tients due to the ocular immune privilege. Nevertheless,* Correspondence: daniel.boehringer@uniklinik-freiburg.de
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long-term success. They give either rise to irreversible
graft failure immediately or at least promote late graft fail-
ure from endothelial cell loss. Penetrating repeat kerato-
plasties due to immunological graft failures are considered
at high immunological risk irrespective of primary indica-
tion. This predicament commonly initiates a vicious cycle
in affected patients due to increased risk of rejections in
consecutive repeat keratoplasties.ral. This is an Open Access article distributed under the terms of the Creative
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Immune reactions cannot currently be sufficiently pre-
vented in the postoperative course of penetrating kerato-
plasty: on average, 18% in normal-risk penetrating
keratoplasty and 75% of high-risk cases are affected - des-
pite standard medical prophylaxis from topical steroids
and in most high-risk situations additional systemic im-
munosuppression. These regimens have to be discontin-
ued at some point in time due to the accumulating risk of
severe adverse drug reactions: topical steroids commonly
induce complications such as cataract or glaucoma. Sys-
temic immunosuppressants like Cyclosporine A or Myco-
phenolate Mofetil may be effective from pilot studies [1]
but have the potential to induce kidney failure as well as
malignancies in the long run. Furthermore, this approach
is hampered by the off-label mode of prescription and
malcompliance.
Considerations on primary prophylaxis
We are aware of no data on the molecular mechanisms
of allorecognition of the corneal graft in the human situ-
ation. However, autologous grafts (such as in auto rota-
tional keratoplasty) are never rejected. Both in-vitro and
in-vivo data point towards a central role of the HLA sys-
tem in eliciting immune reactions. For this reason, a re-
duction of the antigenic load in the graft by means of
matching for HLA and most likely also of further
(’minor’, H) transplantation antigens has a strong poten-
tial to reduce the risk of graft rejections.
Methods/design
The trial is funded by the Deutsche Forschungsgemeinschaft
(DFG). The study received appropriate ethics commit-
tees approval from the central ethics committee (University
of Freiburg, 229/07) and the local ethics committees (Uni-
versity of Erlangen-Nuremberg, 4093-CH; University of
Duisburg-Essen, 09–4134; University of Frankfurt, 234/09;
Medical Association of Hamburg, MC-239/09; Medical
Association of Saarland, 134/09; University of Kiel, B 255/
09; Medical Association of Rheinland-Pfalz, 837.343.09
(6849); Ludwig-Maximilian-University of Munich, 294–
09; University of Muenster, 2009-347-b-S; University of
Wuerzburg, 31/10). Being registered at clinicaltrials.gov
the unique identifying number of the FANCY trial is
NCT00810472. Patient’s written consent was obtained
prior to any study-specific procedures.
Trial design
This is a prospective, controlled, randomised, double-
blind multi-centre clinical trial with two parallel
groups. The intervention is HLA matching for HLA-A, -B
and -DRB1. Donors with less than 3 HLA mismatches are
considered HLA matched. In the matching arm, the first
donor exerting a 4/6 match (or “better“) is acceptedwithin the first three months. A differential matching
strategy on the basis of HLA-Matchmaker is addition-
ally activated thereafter. The next available graft is
assigned after 6 months. In the control arm, the next
available donor is assigned. The matching arm is priori-
tised when a single graft could be allocated to more
than one recipient.
Objectives
The primary objective of the study is to demonstrate su-
periority of the proposed HLA matching strategy in
comparison to random graft assignment with respect to
the endpoint ‘time from keratoplasty to first endothelial
graft rejection’ in penetrating keratoplasty. Secondary
objectives of the study are: assessment of safety and tol-
erability; evaluation of time on waiting list and matching
failures (failure to allocate a matching donor in the HLA
matching arm within 6 months); retrospective analyses
of the number and nature of mismatched antigens (HLA
and minor transplantation antigens) in the patients with
immune reactions; Retrospective analyses on the extent
of antibody production against HLA mismatches in the
rejecting patients.
Setting
A multi-centre study design was chosen to account for
patient recruitment with a reasonable time frame, for in-
clusion of a wider range of patients increasing the generalis-
ability of the results and for the dissemination of findings
when they become available. Trial sites are located in
Erlangen, Essen, Frankfurt, Freiburg, Hamburg, Homburg/
Saar, Kiel, Mainz, Munich, Muenster and Wuerzburg.
Population
The target population of this trial is waiting for penetrat-
ing keratoplasty or lamellar endothelial keratoplasty. The
majority of all indications for corneal transplantation are
eligible for inclusion.
Inclusion criteria
General inclusion criteria are: (1) patient’s written in-
formed consent has been obtained, (2) 18 years or older
at time of informed consent, (3) patient is awaiting ei-
ther penetrating or endothelial lamellar keratoplasty.
Indication-specific inclusion criteria are all corneal con-
ditions that warrant either penetrating or lamellar endo-
thelial keratoplasty.
Exclusion criteria
General exclusion criteria are: (1) patient without legal
capacity who is unable to understand the nature, signifi-
cance and consequences of the study, (2) simultaneous
participation in other interventional trials which could
interfere with this trial and/or participation before the
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a clinical trial within the last thirty days before the start
of this study, (4) previous participation (randomisation) in
this study, (5) known or persistent abuse of medication
and/or drugs (such as alcohol), (6) persons who are in a
relationship of dependence/employment with the sponsor
or the investigator. An indication-specific exclusion criter-
ion is predicted waiting time for a 4/6 HLA match greater
than 6 months. The computation is performed by the trial
software system on the basis of the patient's HLA pheno-
type and the HLA frequencies in the donor pool.
Treatment arms
All randomised trial patients on the waiting lists are
matched against the donor-pool on a continuous basis.
See Figure 1 for an overview of the underlying allocation
algorithm. The matching arm is always prioritised: grafts
are routed into the random arm when there is no match
in the matching arm at time of allocation. Each patient
in the matching arm is assigned a random graft after
6 months. The investigators are notified via email when a
graft has been assigned to a trial patient. Whenever a
keratoplasty is not possible on this basis, the investigator
has to inform the trial coordinator as soon as possible (see
the trial software manual). The waiting time limitation of
6 months in the matching arm is reset in this case.Figure 1 Schematic of the allocation algorithm. The matching arm is p
applicable to the matching arm at time of allocation.Visit schedule
We schedule a total of four follow up visits over a time
span of two years post operatively (see Table 1). At each
visit we ask for assessment of graft clarity and adverse
events. We also demand careful recording of all concomi-
tant medications.
The postoperative treatment and medical aftercare in
corneal transplantation is recommended by the ’Sektion
Kornea’ of the German Ophthalmologic Society (’Deutsche
Ophthalmologische Gesellschaft’) in both study arms.
Treatment of graft rejections is at the discretion of the in-
vestigator and may include topical, intracameral and sys-
temic steroids.
Outcome measures
The primary endpoint is the time interval from kerato-
plasty to the first graft rejection. Graft rejections are de-
fined by either newly diagnosed keratic precipitates or
rejection line in the donor endothelium, subepithelial in-
filtrates not explained by a preceding adenoviral con-
junctivitis or newly diagnosed global graft edema that is
otherwise not explained. The date of graft rejection is
defined as the date on which treatment of the rejection
is initiated. If no treatment was initiated, then the time
of first mention of the rejection in the medical record is
defined as date of the rejection.rioritised: the random arm is only assigned grafts that are not
Table 1 Visit schedule




6 month before keratoplasty
















Concomitant medications x (x)* x x x x
Endothelial cell density x x x x
Details on suturing x (x)*
Details on trephination x (x)*
Slit lamp evaluation of graft x x x x
Adverse events x
Post-OP complications
in the study eye
x x x x
*if data were not requested before.
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matches per patient in the matching arm, (2) number
and nature of mismatched HLA/H transplantation anti-
gens in the rejecting patients, (3) percentage of annual
endothelial cell loss by means of exponential regression
parameters [2,3], (4) referring to substudy: ratio of HLA-
antibody titers in blood samples after graft rejection to
the respective titers prior to keratoplasty.
Sample size
The sample size calculation is based on the primary end-
point ‘time to first endothelial graft rejection’. A rejec-
tion rate of 30% after 2 years is expected in the control
group, and a reduction of events by 30% is considered to
be clinically relevant, corresponding to a rejection rate
of 21% after 2 years in the HLA matched group and a
hazard ratio of 1.51. In order to detect this difference
with a power of 80% at a 2-sided significance level of
alpha = 5%, a total of 184 events is required. In order to
account for the expected 10% match failures because of
the intention-to-treat principle (see below), we randomly
generated 1000 datasets, each with the proposed sample
size of 620 and the expected matching effect of 30% after
3 years against a background of 30% immune reactions.
After introducing 10% matching failures in each of these
datasets, the mean matching effect dropped from 30% to
27%. These results in an assumed rejection rate of 21.9%
in the HLA matched group (instead of 21% without any
matching failures) and a hazard ratio of 1.44 (instead of
1.51). With an accrual period of 1.5 years for and a refer-
ence time of 1.5 years (almost all immune reactions havealready occurred at this postoperative point in time), the
power of the intention to treat analysis is 83%.
Randomisation and blinding
Randomisation is performed, stratified by centre, in
blocks of variable length. An equal distribution between
treatment arms (ratio of 1:1) will be striven for. The ran-
domisation list is generated by the Department of Biometry
and Data Management of the Clinical Trial Unit, Medical
Center – University of Freiburg.
The electronic version of the randomisation list was
integrated in the trial software. Treatment assignment
was thus performed via the trial software. In our study,
this was the best possible way of blinding.
Statistical analysis
The primary analysis of this clinical trial will be conducted
according to the intention-to-treat (ITT) principle. This
means that the patients will be analysed in the treatment
arms to which they were randomised, irrespective of
whether they refused or discontinued the treatment or
whether other protocol violations are revealed. Patients
not receiving keratoplasty cannot contribute any informa-
tion to the analysis of treatment efficacy and will therefore
be excluded from the ITT population.
The primary endpoint ‘time to first graft rejection’ will
be analysed with a Cox proportional hazards model. The
hazard ratio comparing control and treatment group will
be estimated and tested within this model. The 2-sided
95% confidence interval will also be calculated. The Cox
model will be stratified by study centre. We plan to
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actions against the graft and overall graft survival in the
model. Details will be fixed at the latest in a statistical
analysis plan to be prepared prior to the analysis. The
analysis of secondary endpoints ‘number of mismatches
(HLA, H)’ will be performed descriptively, i.e. mean, me-
dian, range, standard deviation, and percentiles will be
given. ‘Time on the waiting list’ will be estimated using
the Kaplan Meier method separately in each treatment
group, where patients not receiving keratoplasty are con-
sidered as censored observations.
Study progress
The recruitment period was extended for another
12 months. During this period, a maximum of 280 pa-
tients were recruited per study centre, leading to a total
of 654 patients.
Quality assurance system
During the clinical trial, quality control and quality as-
surance will be ensured through monitoring, auditing
and supervision by the authorities, if applicable.
An independent Data Monitoring Committee (DMC)
was established. The function of the DMC is to monitor
the course of the study and if necessary to give a recom-
mendation to the study administration for discontinu-
ation, modification or continuation of the study. The
underlying principles for the DMC are ethical and safety
aspects for the patients. It is the task of the DMC to
examine, whether the conducting of the study is still eth-
ically justifiable, whether security of the patients is en-
sured, and whether the process of the study is acceptable.
For this, the DMC has to be informed about the adher-
ence to the protocol, patient recruitment, and the ob-
served adverse events. The DMC may also give a
recommendation to extend the recruitment period and/or
the maximum waiting period in the matching arm in case
of an unexpectedly high percentage of matching failures.
Discussion
FANCY was designed back in 2007. At that time, pene-
trating keratoplasty was the undisputed gold standard
for corneal transplantation. Several trials on HLA
matching in penetrating keratoplasty failed in the past
for various reasons. In the UK, the CTFS II on DR
matching was terminated prematurely because of
under-recruitment [4]. The CCTS had issues with the
typing quality [5]. Eventually, even HLA as the primary
cause of rejection has been questioned on the basis of
rodent experiments [6]. We carefully designed FANCY
to work around all these issues. We abdicated almost all
exclusion criteria, opted for molecular unambiguous
two field HLA typing and included minor antigens into
the analyses.Lamellar techniques turned up at the horizon with
descemet stripping automated endothelial keratoplasty
(DSAEK) as the most prominent variant when we de-
signed FANCY. At that time the immunologic risk in
DSAEK and penetrating keratoplasty was considered
quite comparable. However, during the course of the
trial, Descemet Membrane Endothelial Keratoplasty
(DMEK) became the new method of choice for surgical
endothelial replacement therapy. It came to a big sur-
prise that immune reactions turned out a subordinate
problem with this novel method. This dramatically chan-
ged the landscape of keratoplasty. Nowadays, immune
reactions are a significant clinical problem only in the
high-risk keratoplasties. This is because immunologic
endothelial graft failures after penetrating keratoplasty
e.g. for keratoconus can also be treated with Descemet
Membrane Endothelial Keratoplasty.
The primary goal of FANCY was to assess whether
matching is feasable and effective for all patients within
reasonable time. This is of subordinate relevance in 2014.
If we would redesign FANCY in 2014, we would narrow
down the inclusion criteria to include only the high risk
patients and wait longer for a matching graft.
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